A new bill will centralize the approval process for multinational trials and mandate the publication of trial results—good or bad.
If new results hold up, enhanced phosphorylation of a ribosomal protein may explain the toxicity of mutations that cause Parkinson's.
A small molecule inhibitor kills all microglia in the brain, but the cells rapidly repopulate from a previously unidentified progenitor cell.
Allegations of scientist misconduct led to the retraction of one high-profile stem cell paper and put two others in doubt.
A new study charges that, contrary to previous studies, seeding the mouse brain with aggregated α-synuclein does not trigger a toxic spread of PD-like inclusions in wild-type mice.
Nucleotide repeat expansions in the C9ORF72 gene occur in amyotrophic lateral sclerosis and frontotemporal dementia. Now researchers find the same repeats in patients with two other neurological disorders.
New research suggests that dendritic tau may participate in synaptic plasticity, and that Aβ disrupts this function.
Tirasemtiv, a drug thought to make muscles more sensitive to signals from motor neurons, failed to improve muscle function in people with amyotrophic lateral sclerosis.
Scientists claim that AV-133, an imaging agent that visualizes dopaminergic neurons, can gauge progression of Parkinson’s disease.
Scientists generate human embryonic stem cell lines from adult donor cells, building on earlier studies that showed this was possible with fetal cells.
Marek-Marsel Mesulam received the prestigious award for his research on primary progressive aphasia, a language disorder that can affect people with Alzheimer’s or frontotemporal dementia.
Baby Boomers, keep your blood pressure down. Research is beginning to explain how even mild hypertension, a mid-life risk factor for late-life dementia, might be damaging the neurovascular unit.
By finding differences in gene expression between monocytes and T cells, scientists reveal that the innate immune system has strong ties to neurodegenerative disease.
A small longitudinal study suggests that atrophy begins in the frontoparietal cortex, not the hippocampus, in early Alzheimer's.
European and U.S. agencies approve a third amyloid PET tracer, florbetaben.